Dermapharm Holding SE Overview
Valuation check: DMPHF's ROE is 27.38%, above the sector sector average of 11.75%.
Get informed when a big investor buys or sells
+ Follow27.38%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Dermapharm Holding SE (DMPHF) currently reports a ROE of 27.38%. That is above the sector sector average of 11.75%. Use the charts on this page to explore Dermapharm Holding SE's ROE history and peer comparisons.
Dermapharm Holding SE's ROE of 27.38% is higher than the its sector sector average of 11.75%. That is roughly 132.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Dermapharm Holding SE's current 27.38% should be judged against industry norms (sector average: 11.75%) and against DMPHF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 27.38%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.75%. From there, open related valuation or income-statement pages for Dermapharm Holding SE, and consider following DMPHF for alerts when major investors trade the stock.
